The market may have just started to pick up its stride, but Auris Medical Holding AG (NASDAQ:EARS) has already grabbed the attention of a number of investors as it is up, as of this writing, nearly 30%.
Auris Medical Holding
Headquartered in Zug, Switzerland, Auris Medical Holding is a clinical-stage company that is currently leading the field of therapies that target neurotologic disorders that affect the inner ear.
Perhaps what is most notable about the Zug-based company is that it focuses primarily on developing medicines that target very important medical needs that tend to go unmet in Otolaryngology. For those who don’t know, otolaryngology is a specific medical specialty that focuses on providing aid to anyone suffering from head and/or neck illnesses.
According to Yahoo Finance, Auris Medical Holding has a market capitalization of 26.155 million. Of the 3 analysts covering the company, 3 have a ‘Buy’ rating and 0 have a ‘Sell’ or ‘Hold’ rating.
What Happened?
As of 12:42 p.m. EST, shares of Auris Medical Holding are up 26.88%, which is reasonably good for the clinical-stage company, considering Auris Medical Holding was trading down at the start of the month.
On Thursday, Auris Medical disclosed that it will be providing the public with an update on its development program with AM-111. The update will come on Thursday, January 4, and it will discuss how treatment is going thus far for acute inner ear hearing loss.
The update will be followed by a live conference call hosted by Auris Medical Holdings management team. Additionally, a number of professors from the University of Kansas Medical Center will weigh in their thoughts on the call.
Personally, I will be looking forward to hearing how the development program is going, as according to one professor from the University of Kansas, those who experience sudden deafness find themselves to be both terrified and in shock which can actually lead to chronic hearing loss.
Considering sudden deafness is perhaps one of the most difficult medical conditions to treat, it will be interesting to see how the program has developed as it could be good news for those who are always in need of treatment.
Featured Image: twitter
